quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 5, 2026

Samsara projects FY 2027 revenue of $2.005B-$2.013B while targeting 20% non-GAAP operating margin

View original at seekingalpha.com
Samsara projects FY 2027 revenue of $2.005B-$2.013B while targeting 20% non-GAAP operating margin Earnings Call Insights: Samsara (IOT) Q1 fiscal 2027 MANAGEMENT VIEW * "Samsara delivered a strong start to FY '27, with another quarter of durable and efficient growth" (CEO Sanjit Biswas), including: "We ended Q1 with ne…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q1 revenue was $479 million

    60% confidence
  • Q1 was Samsara's third consecutive quarter of GAAP profitability

    60% confidence
  • Ground Intelligence is priced on a per mile basis

    60% confidence
  • Q1 was another quarter of accelerating growth and improved operating leverage

    60% confidence
  • Revenue grew 31% year-over-year in Q1

    60% confidence
  • The full-year guide raise is almost double the amount of the Q1 beat

    60% confidence
  • Samsara is emphasizing LTM (last 12 months) figures to reduce perceived volatility from large deal timing

    60% confidence
  • There are no changes to hiring plans discussed on the last earnings call

    60% confidence
  • GAAP EPS included a $30 million arbitration award from one of Samsara's lawsuits against Motive

    60% confidence
  • Q2 non-GAAP operating margin expected to be 18%

    60% confidence
  • Samsara's guidance philosophy remains the same and is de-risked for potential downside scenarios

    60% confidence
  • DRAM and NAND supply chain conditions are a little bit tighter

    60% confidence
  • Connected Asset Maintenance adoption is still early in that transition

    60% confidence
  • The Supreme Court ruling on broker liability likely leads to heightened focus on road safety

    60% confidence
  • FY2027 non-GAAP EPS expected to be between $0.70 and $0.72

    60% confidence
  • Samsara is expanding into maintenance, training, qualifications, and workflows

    60% confidence
  • Net new ARR over the last 12 months was $455 million

    60% confidence
  • Samsara is experimenting with different pricing models for new intelligence products

    60% confidence
  • Samsara has confidence it will be able to find the supply it needs

    60% confidence
  • Large customers see an opportunity to bring workflows together on one platform

    60% confidence
  • Q2 non-GAAP EPS expected to be between $0.15 and $0.16

    60% confidence
  • Samsara has only been offering Connected Asset Maintenance for a few quarters now

    60% confidence
  • FY2027 non-GAAP operating margin expected to be 20%

    60% confidence
  • Customer expansions are more driven by more assets or licenses on the same product

    60% confidence
  • Samsara thinks it will be able to keep gross margins roughly flat for FY '27

    60% confidence
  • AI/cloud cost pressure is being mitigated via COGS-related optimizations and OPEX reallocation

    60% confidence
  • Samsara ended Q1 with nearly $2 billion in ARR, growing 30% year-over-year

    60% confidence
  • Waste Intelligence is monetized as additional SKUs

    60% confidence
  • Samsara expects to be GAAP profitable for Q2

    60% confidence
  • Q1 strength was driven by strength in emerging products

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Samsara projects FY 2027 revenue of $2.005B-$2.013B while targeting 20% non-GAAP operating margin — Source | Via News | pt.VIA.NEWS